Physicians Experience with SGLT- 2 Inhibitors In Type 2 Diabetic Patients
Abstract
Background: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients.
Objectives: This study investigates the experience of Pakistani physicians regarding the use of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in the management of Type 2 Diabetes (T2D).
This cross-sectional survey study was conducted from 1st October to December 31st, 2023, enrolled 189 physicians.
Methods: The data was collected by self-administered structured questionnaire which was distributed among physicians across various specialties involved in diabetes care, assessing their views on the efficacy, safety, and economic considerations of SGLT2 inhibitors.
Results: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients. Empagliflozin was the most prescribed among SGLT-2 inhibitor in patients with heart failure. Approximately, 50% of the physicians advise SGLT-2 inhibitor frequently to their patients. Approximately, 81% of the physicians considered efficacious medicine with cost- benefits for their patients and also 89% of them agreed that the cost and quantity of daily diabetes medications impact a patient's overall diabetes management.
Conclusion: The study emphasizes the importance of addressing these economic challenges to enhance the accessibility and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.